ArticleJapanese journal of clinical oncology2026
Outcomes over 30 years after megaprosthetic reconstruction of the lower limb following tumor resection: a retrospective case series of 10 patients.
Article in Japanese journal of clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMegaprosthetic reconstruction has become the standard method for resecting bone and soft tissue tumors. However, the long-term functional outcomes and complications have not yet been sufficiently investigated. This study aimed to address a gap in the literature by analyzing patients who underwent tumor prosthesis of the hip or knee and were followed up for over 30 years.
methodsWe retrospectively analyzed 10 patients who underwent megaprosthetic reconstruction of the hip or knee between 1986 and 1995 at two institutions in Japan, with a minimum follow-up of 30 years. Patient characteristics, complications, reoperation, and Musculoskeletal Tumor Society (MSTS) scores were reviewed. The long-term risks of reoperation, major revision, and deep infection were assessed.
resultsThis study included seven distal femoral, two proximal femoral, and one proximal tibial reconstructions (median age at surgery, 22 years). Histologically, the tumors were predominantly osteosarcomas (n = 7). Eight of the 10 patients (80%) developed complications, with a median of 1.5 reoperations (range, 1-5). Major revisions occurred in five patients, including four with stem fractures and two with deep infections. The median overall reoperation-free survival was 16.2 years (95% confidence interval, 2.4-24.2). At the final follow-up, all patients remained ambulatory, and the median MSTS score was 75.0% (range, 53.3-96.7).
conclusionDespite the occurrence of frequent late complications, considerably long-term survivors following tumor endoprosthetic reconstruction in this small cohort were able to preserve ambulatory function for more than three decades, suggesting the effectiveness of this method while underscoring its lifelong risks and the necessity of long-term follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.